HomeCompareESALY vs PLD

ESALY vs PLD: Dividend Comparison 2026

ESALY yields 31.26% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PLD wins by $6.21M in total portfolio value· pulled ahead in Year 7
10 years
ESALY
ESALY
● Live price
31.26%
Share price
$61.51
Annual div
$19.23
5Y div CAGR
7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$298.7K
Annual income
$71,135.45
Full ESALY calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ESALY vs PLD

📍 PLD pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALYPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALY + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALY pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALY
Annual income on $10K today (after 15% tax)
$2,657.23/yr
After 10yr DRIP, annual income (after tax)
$60,465.13/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $4,407,505.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALY + PLD for your $10,000?

ESALY: 50%PLD: 50%
100% PLD50/50100% ESALY
Portfolio after 10yr
$3.40M
Annual income
$2,663,785.81/yr
Blended yield
78.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ESALY
No analyst data
Altman Z
5.1
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALY buys
0
PLD buys
0
No recent congressional trades found for ESALY or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALYPLD
Forward yield31.26%3.18%
Annual dividend / share$19.23$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7%74.4%
Portfolio after 10y$298.7K$6.50M
Annual income after 10y$71,135.45$5,256,436.18
Total dividends collected$238.7K$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ESALY vs PLD ($10,000, DRIP)

YearESALY PortfolioESALY Income/yrPLD PortfolioPLD Income/yrGap
1$14,045$3,344.99$11,255$555.24+$2.8KESALY
2$19,726$4,698.03$13,062$1,018.59+$6.7KESALY
3$27,705$6,598.37$15,903$1,926.67+$11.8KESALY
4$38,912$9,267.41$20,839$3,823.32+$18.1KESALY
5$54,652$13,016.06$30,464$8,166.08+$24.2KESALY
6$76,759$18,281.04$52,054$19,457.30+$24.7KESALY
7← crossover$107,808$25,675.69$109,886$54,188.93$2.1KPLD
8$151,416$36,061.47$304,030$186,451.18$152.6KPLD
9$212,663$50,648.29$1,166,125$840,813.32$953.5KPLD
10$298,685$71,135.45$6,504,190$5,256,436.18$6.21MPLD

ESALY vs PLD: Complete Analysis 2026

ESALYStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALY Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ESALY vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALY vs SCHDESALY vs JEPIESALY vs OESALY vs KOESALY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.